A5043417410- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Immunodeficiency and Autoimmune Disorders
- Acute Lymphoblastic Leukemia research
- Chronic Myeloid Leukemia Treatments
- Blood groups and transfusion
- Monoclonal and Polyclonal Antibodies Research
- Multiple Myeloma Research and Treatments
- Immune Cell Function and Interaction
- Cutaneous lymphoproliferative disorders research
- Hemoglobinopathies and Related Disorders
- Fungal Infections and Studies
- Galectins and Cancer Biology
- Iron Metabolism and Disorders
- Hematopoietic Stem Cell Transplantation
- Erythrocyte Function and Pathophysiology
- Erythropoietin and Anemia Treatment
- CAR-T cell therapy research
- Glycosylation and Glycoproteins Research
- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- Gastrointestinal Tumor Research and Treatment
- Toxin Mechanisms and Immunotoxins
- Phagocytosis and Immune Regulation
- Genomic variations and chromosomal abnormalities
Karolinska University Hospital
2014-2024
Karolinska Institutet
2013-2024
Sophiahemmet Hospital
1999-2007
Gene Therapy Laboratory
2007
University of Oxford
2004
Heartlands Hospital
2004
Stobhill Hospital
2004
Integrated Cardio Metabolic Centre
2004
Millennium Engineering and Integration (United States)
2004
Leeds General Infirmary
2004
PURPOSE CAMPATH-1H is a human immunoglobulin G1 (IgG1) anti-CD52 monoclonal antibody (MAb) that binds to nearly all B-cell and T-cell lymphomas. We report here the results of multicenter phase II trial in patients with advanced, low-grade non-Hodgkin's lymphoma (NHL) who were previously treated chemotherapy. PATIENTS AND METHODS Fifty had relapsed (n=25) after or resistant (n = 25) chemotherapy 30 mg administered as 2-hour intravenous (i.v.) infusion three times weekly for maximum period 12...
Ibrutinib, a Bruton's tyrosine kinase inhibitor is approved for relapsed/refractory and del(17p)/TP53 mutated chronic lymphocytic leukemia. Discrepancies between clinical trials routine health-care are commonly observed in oncology. Herein we report real-world results 95 poor prognosis Swedish patients treated with ibrutinib compassionate use program. Ninety-five consecutive (93 leukemia, 2 small leukemia) were included the study May 2014 2015. The median age was 69 years. 63% had mutation,...
Background High-resolution genomic microarrays enable simultaneous detection of copy-number aberrations such as the known recurrent in chronic lymphocytic leukemia [del(11q), del(13q), del(17p) and trisomy 12], neutral loss heterozygosity. Moreover, comparison profiles from sequential patients' samples allows clonal evolution.Design Methods We screened 369 patients with newly diagnosed a population-based cohort using 250K single nucleotide polymorphism-arrays. Clonal evolution was evaluated...
Phosphorylation of receptor tyrosine kinases (RTKs) has a key role in cellular functions contributing to the malignant phenotype tumor cells. We and others have previously demonstrated that RTK ROR1 is overexpressed chronic lymphocytic leukemia (CLL). Silencing siRNA downregulated induced apoptosis CLL In present study we analysed isoforms phosphorylation pattern cells (n=38) applying western blot flow-cytometry using anti-ROR1 antibodies an anti-phospho-ROR1 antibody against TK domain. Two...
T-cell immune responses following vaccination with mRNA BNT162b2 against SARS-CoV-2 in patients chronic lymphocytic leukemia: results from a prospective open-label clinical trial *Ab baseline = 0.4 U/mL; seropositive >0.8 U/mL. n 48 (with d35 data).Ab: antibodies; ELISpot: enzyme-linked
Interleukin 4 (IL‐4) is a pleiotropic type II cytokine which has been shown to have direct killing effect on lymphoma and B‐cell chronic lymphocytic leukaemia (B‐CLL) cells in vitro . The clinical effects toxicity of IL‐4 treatment patients with B‐CLL were evaluated. Fourteen who partial remission after chemotherapy received one, two or three 8‐week cycles escalating doses (2, 6 µg/kg/d s.c.) for 3 d/week. Clinical response was analysed each cycle monitored continuously. Ten (71%) had...
This phase II study (n = 20) aimed to evaluate type, severity and duration of side-effects efficacy following subcutaneous (SC) alemtuzumab, without dose-escalation, in advanced-stage relapsed chronic lymphocytic leukaemia (CLL) patients. Alemtuzumab 30 3 mg was administered SC simultaneously day 1, followed by three times per week. Injection-site-reactions were recorded every 6-24 h until resolved using National Cancer Institute criteria a new skin toxicity subscale. The first doses...
Abstract Background: The fluorescence intensities of CD3, CD4 on T cells and CD20, CD22 molecules B were quantitatively measured lymphocytes from chronic lymphocytic leukemia (CLL) patients healthy donors. Methods: performance three different types microbeads was compared, i.e. Quantum equivalent soluble fluorochrome (Q‐MESF), simply cellular (QSC), QuantiBRITE™ (QB). As all PE‐conjugates had a F/P ratio 1:1, the MESF units represented also antibody binding capacity (ABC). Results: ABCs CD20...
Abstract: Five patients with non‐Hodgkin's lymphoma (NHL) and 4 chronic lymphocytic leukaemia (CLL) were treated the CDR‐grafted (rat × human) monoclonal antibody (mAb) Campath‐1H (anti‐CD52). Tumour regression was noted preferentially in peripheral blood bone marrow but lymph nodes less affected. Normal B T cells profoundly reduced all whereas CD16 + NK CD14 monocytes decreased marginally. In responding CLL CD52‐negative not appeared during treatment persisted for several months (4–19+)...